CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 245 enrolled
Drug / intervention
GSK investigational vaccine GSK2340272Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00972517
NCT00972517Phase 3Completed
CompareCT.gov

Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years

GlaxoSmithKline·interventional·Posted Sep 7, 2009·Updated Jun 26, 2019

In Brief

A Phase 3 clinical trial evaluating GSK investigational vaccine GSK2340272A for Influenza. Completed, enrolled 245 participants across 8 sites.

Detailed Summary

The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 7, 2009
Enrollment StartSep 29, 2009
Primary CompletionNov 22, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.8 years ago

Interventions

GSK investigational vaccine GSK2340272Abiological

Three intramuscular injections